Plerixafor Improves Acute Myeloid Leukemia Chemo Efficacy

Posted: March 23, 2012 at 7:07 pm

Editor's Choice Academic Journal Main Category: Lymphoma / Leukemia / Myeloma Article Date: 23 Mar 2012 - 8:00 PDT

email to a friend printer friendly opinions

Current Article Ratings:

5 (1 votes)

The drug blocks these cells from binding to bone marrow by driving them into the bloodstream, where they are more susceptible to chemotherapy.

Geoffrey L. Uy, M.D., co-first author on the study and assistant professor of medicine, said:

52 individuals with acute myeloid leukemia (AML) whose AML was resistant to the standard chemotherapy regimen or who had relapsed, were enrolled to participate in the combined Phase I and II clinical trial. All 46 participants in the Phase II section of the trial received plerixafor. The researchers found that all 46 participants achieved complete remission (no evidence of cancer was found in the bone marrow or blood following treatment).

Uy, who treats patients at the Alivn J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, explained:

Results from earlier studies have demonstrated that mutations that cause AML may vary considerably among patients. Senior author, John F. DiPersio, M.D., Ph.D, the Virginia E. and Sam J. Golman Professor of Medicine, notes that all these leukemia cells, regardless of individual mutations, rely on the protective effects of the bone marrow.

DiPersio, who also treats people at the Siteman Cancer Center, said:

Plerixafor Improves Acute Myeloid Leukemia Chemo Efficacy

Related Post

Comments are closed.